Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMB-101
- Development stage
- Preclinical
- Lead developer
- Ambulero
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
AMB-101 is an allogeneic cell therapy developed by Ambulero, Inc., consisting of mesenchymal stromal cells (MSCs) that are ex vivo transduced to express E-selectin. Known as "Supercharged MSCs," this therapy is designed to treat non-healing wounds and ischemic diseases, such as limb ischemia, by leveraging E-selectin's ability to promote neovascularization and enhance the homing of repair cells to damaged vascular tissues. The therapy has demonstrated the ability to reverse impaired wound healing in animal models and is currently in preclinical development.
- Other names
- Supercharged MSCsE-selectin-expressing allogeneic mesenchymal stromal cells
Beyond the preview
Go deeper on AMB-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMB-101.